The CD3−16+56+ NK cell count independently predicts autologous blood stem cell mobilization
- 1 June 2001
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 27 (12), 1237-1243
- https://doi.org/10.1038/sj.bmt.1703070
Abstract
Better predictive factors for autologous blood stem cell mobilization (BSCM) are needed. The purpose of this study was to determine if an independent association exists between lymphocyte or NK cell counts and BSCM. Data were analyzed on 141 consecutive patients aged 19–69 years (median 45) who received combined chemotherapy plus G-CSF for BSCM, and who had measurements of immune cells prior to BSCM. Of the 141 patients, 41% had breast cancer, 14% Hodgkin's disease, 34% non-Hodgkin's lymphoma, and 11% other diagnoses. BSCM involved dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) plus G-CSF 300 μg (70 kg) for 45% of patients, while the remaining 55% received other chemotherapy plus similar doses of G-CSF. Only a single apheresis was performed for 94% of patients. The following factors were analyzed for predictors of BSCM: age, gender, prior chemotherapy, prior radiotherapy, diagnosis, disease status, marrow involvement, mobilization regimen, Hb, WBC, platelet count, B cell, T cell, and NK cell counts. The peripheral blood CD34+ counts on the first day of apheresis (PBCD34) were 6–1783 × 106/l (median 150). The PBCD34 count correlated strongly with the number of CD34+ cells collected/l blood apheresed and with the number of CD34+ cells collected/kg. By multivariate analysis using continuous variables, relapsed status (P = 0.0003), not using DICEP mobilization (P = 0.0001), female gender (P = 0.0057), low platelet count (P = 0.051), and low CD3−16+56+ count (P = 0.0158) were associated with low PBCD34 counts. Using categorical variables, the only factors that independently predicted a PBCD34 count 1 prior chemotherapy regimen (odds ratio = 5.12, P = 0.0003), not using DICEP mobilization (odds ratio = 4.94, P = 0.0001), and CD3−16+56+ count 6/l (odds ratio = 2.58, P = 0.0157). In conclusion, the CD3−16+56+ count may be a useful additional predictor of BSCM and warrants further study. Bone Marrow Transplantation (2001) 27, 1237–1243.Keywords
This publication has 22 references indexed in Scilit:
- Expression and secretion of vascular endothelial growth factor-A by cytokine-stimulated hematopoietic progenitor cells: Possible role in the hematopoietic microenvironmentExperimental Hematology, 2000
- Selection and use of chemotherapy with hematopoietic growth factors for mobilization of peripheral blood progenitor cellsCurrent Opinion in Hematology, 2000
- Reduced Mobilization of CD34+Stem Cells in Advanced Human Immunodeficiency Virus Type 1 DiseaseThe Journal of Infectious Diseases, 2000
- Management strategies for the hard-to-mobilize patientBone Marrow Transplantation, 1999
- Successful PBSC Mobilization with High-Dose G-CSF for Patients Failing a First Round of MobilizationJournal of Hematotherapy, 1999
- Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimensBone Marrow Transplantation, 1999
- Progenitor cell yields are frequently poor in patients with histologically indolent lymphomas especially when mobilized within 6 months of previous chemotherapyBone Marrow Transplantation, 1998
- Bone marrow steady-state CD34+/CD71− cell content is a predictive value of rG-CSF-mobilized CD34+ cellsBone Marrow Transplantation, 1998
- Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrowBone Marrow Transplantation, 1997
- Chemotherapy‐induced differential changes in lymphocyte subsets and natural‐killer‐cell function in patients with advanced breast cancerInternational Journal of Cancer, 1993